SCHEMBL420965

SCHEMBL420965

CC1=NN(c2ccc3ccccc3c2)C(=O)/C1=C/c1ccc(O)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 8/20 0.58
MEN1 O00255 7/20 0.58
KAT8 Q9H7Z6 1/20 0.57
L3MBTL1 Q9Y468 3/20 0.56
BCL2 P10415 1/20 0.53
BAX Q07812 1/20 0.53
BCL2L1 Q07817 1/20 0.53
KLKB1 P03952 1/20 0.53
CTSB P07858 1/20 0.53
GAA P10253 1/20 0.52
AMY1A P0DUB6 3/20 0.51
POLB P06746 2/20 0.51
ALDH1A1 P00352 3/20 0.48
KDM4E B2RXH2 2/20 0.48
PSMD14 O00487 1/20 0.48
USP2 O75604 1/20 0.48
MAPT P10636 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
SAE1 Q9UBE0 1/20 0.48
UBA2 Q9UBT2 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL446478 0.85 KMT2A (0.76) KMT2AMEN1KAT8L3MBTL1GAA
SCHEMBL420808 0.85 KMT2A (0.76) KMT2AMEN1KAT8L3MBTL1GAA
SCHEMBL447476 0.82 KMT2A (0.67) KMT2AMEN1KAT8L3MBTL1KLKB1
SCHEMBL419549 0.82 KMT2A (0.67) KMT2AMEN1KAT8L3MBTL1KLKB1
SCHEMBL29517905 0.79 KMT2A (0.57) KMT2AMEN1KAT8L3MBTL1BCL2
SCHEMBL420572 0.78 AMY1A (0.56) KMT2AMEN1KAT8L3MBTL1GAA
SCHEMBL443203 0.78 KAT8 (0.81) KMT2AMEN1KAT8L3MBTL1AMY1A
SCHEMBL420591 0.78 KAT8 (0.81) KMT2AMEN1KAT8L3MBTL1AMY1A
SCHEMBL8078405 0.78 KAT8 (0.81) KMT2AMEN1KAT8L3MBTL1AMY1A
SCHEMBL444177 0.78 AMY1A (0.56) KMT2AMEN1KAT8L3MBTL1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140335517-A1 DETECTION AND TREATMENT OF SCHIZOPHRENIA RENASCIENCE CO LTD (JP) 2014-11-13 US disclosed
US-20140335517-A1 DETECTION AND TREATMENT OF SCHIZOPHRENIA RENASCIENCE CO LTD (JP) 2014-11-13 US disclosed
US-8809329-B2 Detection and treatment of schizophrenia TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE (JP) 2014-08-19 US disclosed
US-8809329-B2 Detection and treatment of schizophrenia TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE (JP) 2014-08-19 US disclosed
US-20120065198-A2 Detection and Treatment of Schizophrenia TOKAI UNIVERSITY EDUCATIONAL SYSTEM (JP) 2012-03-15 US disclosed
US-20120065198-A2 Detection and Treatment of Schizophrenia TOKAI UNIVERSITY EDUCATIONAL SYSTEM (JP) 2012-03-15 US disclosed
US-20110028470-A1 Detection and Treatment of Schizophrenia TOKAI UNIVERSITY EDUCATIONAL SYSTEM (JP) 2011-02-03 US disclosed
US-20110028470-A1 Detection and Treatment of Schizophrenia TOKAI UNIVERSITY EDUCATIONAL SYSTEM (JP) 2011-02-03 US disclosed
US-7645882-B2 Inhibitor of protein modification products formation TOKAI UNIVERSITY EDUCATIONAL SYSTEM (JP) 2010-01-12 US disclosed
US-7645882-B2 Inhibitor of protein modification products formation TOKAI UNIVERSITY EDUCATIONAL SYSTEM (JP) 2010-01-12 US disclosed
US-20070123577-A1 Inhibitor of protein modification products formation TOKAI UNIVERSITY EDUCATIONAL SYSTEM (JP) 2007-05-31 US disclosed
US-20070123577-A1 Inhibitor of protein modification products formation TOKAI UNIVERSITY EDUCATIONAL SYSTEM (JP) 2007-05-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070123577-A1 Inhibitor of protein modification products formation SERPINB6, PROC, PLPBP KMT2A 2334/4885MEN1 1277/4885KAT8 2951/4885
US-20110028470-A1 Detection and Treatment of Schizophrenia GLO1, CBR1, AOX1 KMT2A 1703/4885MEN1 4818/4885KAT8 2833/4885
US-20120065198-A2 Detection and Treatment of Schizophrenia GLO1, CBR1, AOX1 KMT2A 1703/4885MEN1 4818/4885KAT8 2833/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.